Skip to content. | Skip to navigation

Personal tools
Log in
You are here: Home News News archive Van Deventer appointed to Supervisory Board of AMT

Van Deventer appointed to Supervisory Board of AMT

Professor Sander van Deventer has been appointed to the Supervisory Board of Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy.

Professor van Deventer is one of AMT’s co-founders. He was Professor and Head of the Department of Experimental Medicine, Chairman at the Department of Gastroenterology of the AMC from 2002 to 2004, and subsequently Professor of Experimental Medicine at the University of Amsterdam Medical School until 2008. He has over 15 years experience in biotechnology product development. He is the author of more than 350 scientific articles in peer-reviewed journals and serves as an advisor to regulatory authorities including the EMA and FDA.

Professor van Deventer served on the Management Board of AMT as Chief Scientific Officer until February 2009, and temporarily also as Chief Executive Officer from February - October 2009. He currently chairs the Scientific Advisory Board of AMT. He is also a partner of Forbion Capital, a shareholder in the Company, and Professor of Translational Gastroenterology at the Leiden University Medical Center (LUMC).

Also at the Annual General Meeting Mr Piers Morgan, CFO, was appointed to the Management Board and Mr Alexander Ribbink retired as a member of the Supervisory Board.

More information

Document Actions
Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...

Submit a news item!

News

Partners in the Cluster can submit news items to be circulated widely via the homepage of the Amsterdam BioMed Cluster.

Or add us to your mailing list for press releases: info[at]amsterdambiomed.nl

Find your life sciences partner in the Amsterdam BioMed Cluster

Find your life sciences partner in the Amsterdam BioMed Cluster